Skip to content
Screener

Spyre Therapeutics, Inc. SYRE Q2 2025 earnings

Reported August 5, 2025 · Before market open

Revenue-
EPS-$0.49Beat by $0.24
EPS estimate-$0.73

Next report

Nov 3, 2026 (in 2 months)
EPS estimate-$0.80

Financials

Q2 2025

Income statement

See full
Revenue-—
Operating income-$41.9M+5.0%
Net income-$36.7M+5.5%
EPS (diluted)-$0.49+43.0%

Balance sheet

See full
Cash & equivalents$81.7M+79.6%
Total equity$455.8M+21.7%
Total assets$538.8M+23.6%

Cash flow

See full
Operating cash flow-$46.6M+25.2%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$930.05M-22.1%

Returns & leverage

See full
Return on equity-49.8%—
Current ratio6.5×-13.2×

Segments

By segment

See full
Reportable Segment-—

FAQ

When did Spyre Therapeutics, Inc. report Q2 2025 earnings?
Spyre Therapeutics, Inc. (SYRE) reported Q2 2025 earnings on August 5, 2025 before market open.
What were Spyre Therapeutics, Inc.'s Q2 2025 revenue and EPS?
Spyre Therapeutics, Inc. reported revenue of - and eps of $-0.49 for Q2 2025.
Did Spyre Therapeutics, Inc. beat estimates in Q2 2025?
EPS beat the consensus estimate of $-0.73 by $0.24.
How did Spyre Therapeutics, Inc.'s Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 43.0% from $-0.86.
Where can I find Spyre Therapeutics, Inc.'s Q2 2025 SEC filings?
You can read the 8-K earnings release (0001636282-25-000091) and the 10-Q periodic report (0001636282-25-000089) directly on SEC EDGAR. The filing index links above go to sec.gov.